PaxMedica (PXMD) Competitors $0.0002 0.00 (0.00%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock PXMD vs. CMRA, GNCAQ, GNCA, ARDS, STAB, EFTR, AMPE, ONCSQ, ATNFW, and LBPSWShould you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), Ampio Pharmaceuticals (AMPE), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), and 4D pharma (LBPSW). These companies are all part of the "pharmaceutical products" industry. PaxMedica vs. Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Ampio Pharmaceuticals OncoSec Medical 180 Life Sciences 4D pharma Comera Life Sciences (NASDAQ:CMRA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Which has higher valuation & earnings, CMRA or PXMD? Comera Life Sciences has higher revenue and earnings than PaxMedica. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.01-$18MN/AN/APaxMedicaN/AN/A-$18.29MN/AN/A Do insiders and institutionals believe in CMRA or PXMD? 4.9% of PaxMedica shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer CMRA or PXMD? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral PaxMedica Neutral Is CMRA or PXMD more profitable? Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A PaxMedica N/A -3,167.89%-560.35% Does the MarketBeat Community prefer CMRA or PXMD? PaxMedica received 1 more outperform votes than Comera Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformComera Life SciencesN/AN/APaxMedicaOutperform Votes1100.00% Underperform VotesNo Votes Which has more volatility and risk, CMRA or PXMD? Comera Life Sciences has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. SummaryComera Life Sciences beats PaxMedica on 6 of the 8 factors compared between the two stocks. Remove Ads Get PaxMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address PXMD vs. The Competition Export to ExcelMetricPaxMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2,000.00$6.91B$5.63B$7.83BDividend YieldN/A2.79%5.33%4.02%P/E RatioN/A7.2923.6418.75Price / SalesN/A218.91381.8790.87Price / CashN/A65.6738.1734.64Price / Book0.006.386.874.23Net Income-$18.29M$142.34M$3.20B$247.47M7 Day PerformanceN/A-5.83%-3.58%-3.56%1 Month PerformanceN/A-7.55%1.49%-5.81%1 Year PerformanceN/A-11.06%9.11%-0.96% PaxMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PXMDPaxMedicaN/A$0.00flatN/AN/A$2,000.00N/A0.002CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/A$0.00+∞N/AN/A$6,000.00N/A0.0070Gap UpGNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+3,999,900.0%N/A$3,000.00$3.55M0.0010AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$2,000.00N/A0.0020Analyst ForecastONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040ATNFW180 Life SciencesN/A$0.01+6.1%N/A-7.3%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/A Remove Ads Related Companies and Tools Related Companies CMRA Alternatives GNCAQ Alternatives GNCA Alternatives ARDS Alternatives STAB Alternatives EFTR Alternatives AMPE Alternatives ONCSQ Alternatives ATNFW Alternatives LBPSW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PXMD) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PaxMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PXMD Stock Free PXMD Stock Alerts